19. Bordás P, Jonsson H, Nyström L, Lenner P. Survival from invasive breast cancer among interval cases in the mammography screening programmes of northern Sweden. Breast. 2007; 16: 47–54. PMID: 16875820

20. Zackrisson S, Janzon L, Manjer J, Andersson I. Improved survival rate for women with interval breast cancer—results from the breast cancer screening programme in Malmö, Sweden 1976–1999. J Med Screen. 2007; 14: 138–143. PMID: 17925086

21. Brekelmans CT, Peeters PH, Deurenberg JJ, Collette HJ. Survival in interval breast cancer in the DOM screening programme. Eur J Cancer. 1995; 31A: 1830–1835. PMID: 8541108

22. Ministry of Health, Labour and Welfare. Medical Institute Survey, 2011. 2012. Available: http://www.e-stat.go.jp/SG1/estat/GL08020101.do?_toGL08020101_&tstatCode=000001030908&requestSender = dsearch

23. Sobue T. Current activities and future directions of the cancer registration system in Japan. Int J Clin Oncol. 2008; 13: 97–101. doi: 10.1007/s10147-008-0761-7 PMID: 18463951

24. Matsuda T, Sobue T. Recent trends in population-based cancer registries in Japan: the Act on Promotion of Cancer Registries and drastic changes in the historical registry. Int J Clin Oncol. 2015; 20: 11–20. doi: 10.1007/s10147-014-0765-4 PMID: 25351534

25. Okamoto N. A history of the cancer registration system in Japan. Int J Clin Oncol. 2008; 13: 90–96. doi: 10.1007/s10147-008-0759-1 PMID: 18463950

26. Sobue T, Matsuda T, Shibata A, Matsuda A. Monitoring of Cancer Incidence in Japan 2007. Tokyo: National Cancer Center, Center for Cancer Control and Information Services; 2012 pp. 140.

27. Research Group for Survival statistics of Japanese association of Clinical Cancer Centers. Survival analysis of cancer patients by the Kaplan-Meier method. 2012. Available: http://www.gunma-cc.jp/sarukihan/seizonritu/index.html.

COMMENTARY

Have we Comprehensively Evaluated the Effectiveness of Endoscopic Screening for Gastric Cancer?

Chisato Hamashima

Abstract

Endoscopy has been increasingly used in clinical practice and as a standardized examination procedure for gastrointestinal diseases. However, only a few studies on endoscopic screening for evaluating mortality reduction from gastric cancer have been carried out. Even if a high detection rate is obtained in clinical practice, such a rate cannot be directly accepted as evidence providing the effectiveness of cancer screening. Endoscopic screening for gastric cancer is not an exception of possibility to detect overdiagnosis. If detection rate is used for the evaluation of the effectiveness of cancer screening, the possibility of overestimating the effectiveness of cancer screening cannot be ruled out. To avoid the effect of overdiagnosis and confirm the effectiveness of endoscopic screening, mortality reduction from gastric cancer must be carefully evaluated by conducting reliable studies. The burden of gastric cancer remains real and this cannot be ignored in Eastern Asian countries. To determine the best available method for gastric cancer screening, evaluation of its effectiveness is a must. Endoscopic screening for gastric cancer has shown promising results, and thus deserves further comprehensive evaluation to reliably confirm its effectiveness and how its optimal use can be strategically promoted.

Keywords: Gastric cancer screening - upper gastrointestinal endoscopy - mortality reduction - overdiagnosis

Asian Pac J Cancer Prev, **16 (8)**, 3591-3592

Endoscopy has been increasingly used in clinical practice and as a standardized examination procedure for gastrointestinal diseases. Notably, the uses of upper gastrointestinal series with barium meal for diagnostic examination have progressively decreased. This situation has ushered the gradual introduction of endoscopic screening in clinical settings. In fact, high detection rates of gastric cancer have been reported with endoscopic screening (Tashiro et al., 2006; Lu et al., 2014). Regarding effectiveness, there is great expectation that endoscopic screening has a high possibility of reducing mortality from gastric cancer. However, only a few studies on endoscopic screening for evaluating mortality reduction from gastric cancer have been carried out. To evaluate the effectiveness of cancer screening, the appropriate target population and study design with final outcomes should be identified. The European guidelines for quality assurance in cervical cancer screening previously defined the ranking of study designs and outcomes for the evaluation of cervical cancer screening (International Agency for Research on Cancer, 2006). The basic concept can be adopted for the assessment of endoscopic screening. To confirm the effectiveness of endoscopic screening, the following basic requirements should be included in the evaluation points: target population, outcome, and study design.

The target of cancer screening is an asymptomatic individual with an average risk, which is different from individuals presenting with symptoms. Even if a high detection rate is obtained in clinical practice, such rate cannot be directly translated as evidence providing the effectiveness of cancer screening. The target subjects are usually different between cancer screening and clinical practice. In a previous Japanese study, although the subjects of endoscopic screening were the selected participants who were examined by multiphasic health check-up, the comparators were selected from patients in the hospital (Hosaokawa et al., 2008). To evaluate the effectiveness of endoscopic screening, comparators should also be chosen from the asymptomatic population. This is because patients might have risks of gastric cancer even if they did not have examination histories of upper gastrointestinal series with barium meal and endoscopy.

The effectiveness of cancer screening should be evaluated based on mortality reduction from cancer. Although the detection rate is often reported as the outcome measure in cancer screening, it is not a preferable indicator for showing evidence regarding the effectiveness of cancer screening. Cancers detected by screening include early stages of gastric cancer which has a possibility to progress to the death of the individual or overdiagnosis cases. Overdiagnosis is defined as the detection of cancers that might never progress to manifest symptoms during a person's life and it could not be the cause of death (International Agency for Research on Cancer, 2002). Since overdiagnosis leads to unnecessary examinations and overtreatment, patients who are diagnosed as having

*Cancer Screening Assessment and Management Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan *For correspondence: chamashi@ncc.go.jp*

indolent cancers do not have any benefit from cancer screening. Endoscopic screening for gastric cancer is not an exception. Endoscopy can detect cases of early stage cancer which is often the target for endoscopic surgical resection. Although there is currently no report of overdiagnosis for gastric cancer screening, the numbers of detected cancer by endoscopic screening were twice the expected numbers (Hamashima et al., 2006). These cases might be included in the overdiagnosis cases. If detection rate is used for the evaluation of the effectiveness of cancer screening, the possibility of overestimating the effectiveness of cancer screening cannot be ruled out. To avoid the effect of overdiagnosis and confirm the effectiveness of endoscopic screening, mortality reduction from gastric cancer must be carefully evaluated by conducting reliable studies.

The most reliable method for evaluating mortality reduction is a randomized controlled trial (RCT) (International Agency for Research on Cancer, 2006). In fact, the efficacies of mammographic screening and colorectal cancer screening using fecal occult blood test have been evaluated by RCTs. However, the previous results related to such effectiveness of gastric cancer screening were solely based on a few observational studies (Hamashima et al., 2008). Recently, our group has published the results of a community-based case-control study to evaluate the effectiveness of endoscopic screening for gastric cancer. The findings of this study suggest a 30% reduction in gastric cancer mortality by endoscopic screening within 36 months before the date of gastric cancer diagnosis (Hamashima et al., 2013). Interestingly, a Korean study also reported a 57% mortality reduction by endoscopic screening of a nested case-control study based on the national database (Cho, 2014). These results suggest a high possibility of achieving mortality reduction from gastric cancer by endoscopic screening. However, the results have been obtained from observational studies only. Realistically, it is difficult to perform RCT for endoscopic screening in Korea and Japan, countries that have already established national programs for gastric cancer screening (Oshima, 1994; Kim et al., 2011). Although case-control and cohort studies are the second best methods, there is a serious need for the accumulation of more valid evidence from Asian countries if the introduction of endoscopic screening to communities is to be realized.

The burden of gastric cancer remains real and this cannot be ignored in Eastern Asian countries. To determine the best available method for gastric cancer screening, evaluation of its effectiveness is a must. Endoscopic screening for gastric cancer has shown promising results, and thus deserves further comprehensive evaluation to reliably confirm its effectiveness and how its optimal use can be strategically promoted.

Acknowledgements

The author thanks Dr. Edward Barroga, Senior Medical Editor of Tokyo Medical University, for editing the manuscript.

References

Cho BY (2014). Evaluation of the validity of current national health screening programs and plans to improve the system. pp.741-58. Seoul University. Seoul. (in Korean).

Hamashima C, Sobue T, Muramatsu Y, et al (2006). Comparison of observed and expected numbers of detected cancers in the research center for cancer prevention and screening program. *Jpn J Clin Oncol*, **36**, 301-8.

Hamashima C, Shibuya D, Yamazaki H, et al (2008). The Japanese guidelines for gastric cancer screening. *Jpn J Clin Oncol*, **38**, 259-67.

Hamashima C, Ogoshi K, Okamoto M, et al (2013). A community-based, case-control study evaluating mortality reduction from gastric cacner by endoscopic screening in Japan. *PLOS One*, **8**, e79088.

Hosokawa O, Miyanaga T, Kaizaki Y, et al (2008). Decreased death from gastric cancer by endoscopic screening: association with a population-based cancer registry. *Scand J Gastroenterol*, **43**, 1112-5.

International Agency for Research on Cancer (2002). IARC Handbook of Cancer Prevention: Breast Cancer Screening.p.220. IARC press. Lyon.

International Agency for Research on Cancer (2006). European guidelines for quality assurance in cervical cancer screening second edition. p. 74. IARC press. Lyon.

Kim Y, Jun JK, Choi KS, et al (2011). Overview of the national cancer screening programme and the cancer screening status in Korea. *Asian Pac J Cancer Prev*, **12**, 725-73.

Lee YC, Chen TH, Chiu HM, et al (2013). The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. *Gut*, **62**, 676-82.

Lu YF, Liu ZC, Li ZH, et al (2014). Esophageal/gastric cancer screening in high-risk populations in Henan Province, China. *Asian Pac J Cancer Prev*, **15**, 1419-22.

Oshima A (1994). A critical review of cancer screening programs in Japan. *Int J Technol Assess Health Care*, **10**, 346-58.

Tashiro A, Sano M, Kinameri K, et al (2006). Comparing mass screening techniques for gastric cancer in Japan. *World J Gastroenterol*, **12**, 4873-4.

JJCO Japanese Journal of Clinical Oncology

Japanese Journal of Clinical Oncology, 2016, 46(5) 482–492
doi: 10.1093/jjco/hyw008
Advance Access Publication Date: 18 February 2016
Public Health Report

OXFORD

Public Health Report

The Japanese Guidelines for Breast Cancer Screening

Chisato Hamashima*on behalf of the Japanese Research Group for the Development of Breast Cancer Screening Guidelines

Division of Cancer Screening Assessment and Management, Center for Public Health Sciences, National Cancer Center, Chuo-ku, Tokyo, Japan

*For reprints and all correspondence: Chisato Hamashima, Division of Cancer Screening Assessment and Management, Center for Public Health Sciences, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. E-mail: chamashi@ncc.go.jp

Received 7 September 2015; Accepted 10 January 2016

Abstract

Objective: The incidence of breast cancer has progressively increased, making it the leading cause of cancer deaths in Japan. Breast cancer accounts for 20.4% of all new cancers with a reported age-standardized rate of 63.6 per 100 000 women.

Methods: The Japanese Guidelines for Breast Cancer Screening were developed based on a previously established method. The efficacies of mammography with and without clinical breast examination, clinical breast examination and ultrasonography with and without mammography were evaluated. Based on the balance of the benefits and harms, recommendations for population-based and opportunistic screenings were formulated.

Results: Five randomized controlled trials of mammographic screening without clinical breast examination were identified for mortality reduction from breast cancer. The overall relative risk for women aged 40–74 years was 0.75 (95% CI: 0.67–0.83). Three randomized controlled trials of mammographic screening with clinical breast examination served as eligible evidence for mortality reduction from breast cancer. The overall relative risk for women aged 40–64 years was 0.87 (95% confidence interval: 0.77–0.98). The major harms of mammographic screening were radiation exposure, false-positive cases and overdiagnosis. Although two case–control studies evaluating mortality reduction from breast cancer were found for clinical breast examination, there was no study assessing the effectiveness of ultrasonography for breast cancer screening.

Conclusions: Mammographic screening without clinical breast examination for women aged 40–74 years and with clinical breast examination for women aged 40–64 years is recommended for population-based and opportunistic screenings. Clinical breast examination and ultrasonography are not recommended for population-based screening because of insufficient evidence regarding their effectiveness.

Key words: breast cancer, cancer screening, mammography, clinical breast examination, ultrasonography, meta-analysis, systematic review, guideline

Introduction

The incidence of breast cancer has progressively increased in many countries and it has become one of the leading causes of cancer deaths in Japan. Breast cancer accounts for 20.4% of all new cancers in Japan with an age-standardized rate of 63.6 per 100 000 women (1).

Most developed countries have provided mammographic screening mainly for women aged 50–69 years (2). Interestingly, although

the incidence of breast cancer in western countries has increased according to age (3), mammographic screening for women aged 40–49 years has not been provided because it remains unclear whether its benefits outweigh its harms in this particular age group (4–7). Compared with western countries, the age distribution of breast cancer is different in Japan, with the highest incidence rate observed in women aged 45–49 years (1). Therefore, the burden of breast cancer for this age group cannot be ignored in Japan despite the absence of studies evaluating mortality reduction using mammography for Japanese women aged 40–49 years. Admittedly, there has been insufficient discussion whether or not it is appropriate to include women in their 40s as a target group for breast cancer screening in the Japanese program, particularly from the perspective of the balance of benefits and harms.

In their evidence report in 2001, Hisamichi et al. (8) recommended the combination of mammography and clinical breast examination for breast cancer screening. However, their report did not clearly specify the reason for the non-recommendation of mammographic screening without clinical breast examination. Although clinical breast examination and ultrasonography have also been evaluated, these methods were not recommended because of insufficient evidence regarding their effectiveness. Since 2000, a combination of mammography and clinical breast examination has been recommended as population-based screening in Japanese communities. Notably, mammographic screening without clinical breast examination was not recommended as a breast cancer screening option even though it is the most common method used in developed countries.

Since the publication of the previous reports by Hisamichi et al., new studies on mammographic screening including women aged 40–49 years and ultrasonography for the breast have been reported worldwide. Nevertheless, evidence regarding the efficacy of mammographic screening has remained controversial, spurring ongoing discussion with regard to its application (3–6,9,10). Subsequently, a new Japanese research group has established a standardized method for developing the Japanese Guidelines for Cancer Screening (11). Based on this method, the efficacy and effectiveness of mammography with and without clinical breast examination, clinical breast examination alone and ultrasonography with and without mammography for breast cancer screening were evaluated, and new guidelines were developed.

Methods

The target audiences for the breast cancer screening guidelines include the public, health professionals working in cancer screening programs, providers of cancer screening programs and policy makers. The members of the Japanese Research Group for Development of Breast Cancer Screening Guidelines were selected from various specialties, including primary care physicians, breast surgeons, radiologists and epidemiologists. The breast cancer screening guidelines were developed using the standardized method which was defined as the development method for the Japanese guidelines for cancer screening (11).

Target screening methods

Mammography with and without clinical breast examination, clinical breast examination and ultrasonography with and without mammography were evaluated in terms of their efficacy and effectiveness for breast cancer screening. In most developed countries, mammographic screening without clinical breast examination has been the standard method for breast cancer screening (2). However, in Japan, mammographic screening with clinical breast examination has been the method recommended and performed since 2000. Clinical breast examination alone was used for breast cancer screening from 1987 to 2003 as population-based screening in Japan. Recently, ultrasonography with and without mammography has been performed in a clinical setting as opportunistic screening, particularly for women aged 40–49 years.

The primary issue regarding the guidelines was evaluation of the efficacy of mammographic screening with and without clinical breast examination. The secondary issue was evaluation of the efficacy of mammographic screening for women aged 40 years.

Analytic framework

The target population for breast cancer screening was defined as asymptomatic women with an average risk of breast cancer. To select appropriate evidence, an analytic framework for breast cancer screening was developed (Fig. 1). For each stage of the analytic framework, clinical questions based on the PICO (population, intervention, comparison and outcome) format were prepared. Direct evidence was defined as evidence provided by a study that evaluated the efficacy and effectiveness of cancer screening for reducing breast cancer incidence and mortality (Fig. 1, arrow 1). Other studies that provided indirect evidence were selected on the basis of clinical questions related to other stages of the analytic framework (Fig. 1, arrows 2–8).

Systematic literature review

To select appropriate evidence for our clinical questions, a two-stage review was performed: (i) the title and abstract were initially checked and (ii) the text of the potentially relevant full papers was subsequently reviewed (11). Two reviewers screened the abstracts individually. Subsequently, they reviewed the full papers of potentially relevant studies.

The inclusion criteria for article selection were original articles published after peer review (11). The study design and outcome were defined differently among the screening methods, and the detailed inclusion criteria were described in the screening method section. The common exclusion criteria among all the screening methods were as follows: (i) no abstract, (ii) study in which the target screening group was composed of symptomatic persons (patients), (iii) economic evaluation study, (iv) guidelines, evidence reports and reviews, and (v) official statistics, letters and personal communications.

To select appropriate evidence, a systematic review of the retrieved articles was conducted using the checklist according to the study design, and the quality of the studies was defined. If the decision regarding the full paper review was inconsistent, the appropriateness of these studies was carefully discussed. Finally, adequate studies were selected for evaluation of breast cancer screening.

The evidence for each screening method was summarized in an evidence table based on the analytic framework's clinical questions. The body of evidence for each screening modality was determined according to the level of evidence which was defined on the basis of the study design, quality and consistency among the study results (11).

Mammographic screening

To identify the efficacy of mammographic screening with and without clinical breast examination, PubMed, Web of Science, Igaku-Cyuo zasshi and J Dream were searched for studies using search terms such as 'breast cancer', 'mammography', 'clinical breast examination', 'physical breast examination' or 'mortality reduction', from January 1985 to April 2012. Additional references recommended were identified and included as needed. If the result from a new result of a large-scale randomized controlled trial (RCT) based on an extended



Figure 1. Analytic framework and key questions for breast cancer screening. The numbers in the analytic framework refer to the following clinical questions. (1) Compared with no screening (or other screening strategies), is there direct evidence that the mortality from breast cancer is reduced with the following screening methods? (a) Clinical breast examination (CBE). (b) Mammography (MMG). (c) Mammography with clinical breast examination (MMG + CBE). (d) Ultrasonography with and without mammography (US ± MMG). To appropriately determinate the level of evidence, the primary outcomes of mortality from breast cancer must be ascertained. (2) What age group was the preferable target for breast cancer screening? (3) Can the screening test accurately detect breast cancer? What are the sensitivity and specificity rates of the screening test? (4) What are the potential harms of screening tests, and how often do they occur? (5) Can the diagnostic test accurately detect the target women? (6) What are the potential harms of diagnostic tests, and how often do they occur? 7) (For breast cancer patients, how are the efficacy and effectiveness of treatment?

follow-up was published, the study was included. Articles with revised results based on an extended follow-up and other RCTs regarding mammographic screening were also searched from April 2012 to December 2014 to evaluate mortality reduction from breast cancer. The searches were limited to English-language or Japanese-language publications. The study design was limited to RCTs to evaluate mortality reduction from breast cancer. The RCTs for mammographic screening with and without clinical breast examination compared with a no screening group or the usual care were selected. Modeling studies were not included for evaluation of the studies to reduce mortality from breast cancer. The meta-analysis results were published in other articles and referred to for the guidelines development. In this article, we reported detailed information regarding the evaluation of study quality (11). Although the follow-up years varied among the studies, the results of 13 years follow-up from the Cochrane review (9) and original data from selected articles were cited. Meta-analysis for RCTs of mammographic screening with and without clinical breast examination was performed for women of different age groups as follows: women aged 40–74 years (all age group), women aged 40–49 years and women aged 50 years and over (12). For studies that reported cumulative count data, we carried out a Mantel-Haenszel fixed-effects meta-analysis to obtain the relative risk and risk difference with the corresponding 95% confidence interval (CI). The results of the meta-analysis have been published in above-mentioned article.

Other methods and harms

To identify the effectiveness of clinical breast examination and ultrasonography, PubMed, Web of Science, Igaku-Cyuo zasshi and J Dream were searched for studies from January 1985 to April 2012 using search terms such as 'breast cancer', 'clinical breast examination', 'physical breast examination', 'ultrasonography' or 'mortality reduction'. Observational studies were included for the evaluation of clinical breast examination and ultrasonography. Studies that analyzed sensitivity and specificity were also included. Additional references recommended were identified and included as needed.

Articles related to overdiagnosis, false-positive cases, radiation exposure of mammographic screening and adverse effects of needle biopsy were also searched using the same method, and evidence from RCTs and observational studies was identified. Modeling studies were included for the evaluation of overdiagnosis, false-positive cases and radiation exposure.

Translation into recommendations

To compare the benefits and harms, number needed to invite (NNI) was calculated on the basis of the mortality rate from breast cancer in Japanese women. The results of NNI calculation published in other articles (12) were referred to for the guidelines development. NNI refers to the number needed to avoid one breast cancer death. NNI can show the impact of the benefits of cancer screening as well as harms, as unnecessary examinations increase with increasing NNI. A high recall rate for diagnostic examination can also be considered harms for mammographic screening participants owing to an increase in unnecessary examinations. The number needed for diagnostic examination to avoid one breast cancer death was also calculated on the basis of the recall rate of mammographic screening in communities (12). These results were compared between mammographic screening

with and without clinical breast examination divided into different age groups from 40 to 70 years.

Considering the balance of benefits and harms, five grades of recommendations were determined for population-based and opportunistic screenings (10). As theses grades are supported by sufficient evidence and the benefits outweigh the harms, both Grades A and B recommendations could be conducted as both population-based and opportunistic screening programs. However, a method with a Grade D recommendation should not be used for either population-based or opportunistic screening programs because the harms outweigh the benefits. A grade C recommendation implies that the method should not be used for population-based screening. Even if there are benefits, we can give a Grade C recommendation when the benefits and harms are nearly equal. However, a Grade C recommendation implies that the method could be used in clinical settings if both adequate risk management and informed consent with respect to the harms were assured. Screening methods that have insufficient evidence related to mortality reduction from breast cancer are graded as I; such methods are not recommended for population-based screening or as routine screening methods in clinical settings, although the decision to undergo screening could be made at the individual level based on proper information provided by health professionals in clinical settings.

Formulating the guidelines

A draft of the guidelines has been written and uploaded on the 'Promoting Evidence-based Cancer Screening' website (http://canscreen.ncc.go.jp/). To improve and confirm the guidelines, comments from the public were collected. In addition, major issues identified during the review of the draft were discussed at a guidelines forum open to the public. Taking into account the comments received from external reviewers and the guidelines forum, the appropriateness of the recommendation and its language were re-discussed and the guidelines were refined. After the consultations were completed, the guidelines were approved by the National Cancer Center and published on the 'Promoting Evidence-based Cancer Screening' website (http://canscreen.ncc.go.jp/).

Findings

Evidence of the efficacy and effectiveness of breast cancer screening methods

There were 5270 articles identified from the literature search using PubMed and other databases. After a two-stage review, 110 English articles and 8 Japanese articles were selected (Fig. 2). From these 110 articles, 6 RCTs for mammographic screening without clinical breast examination were identified as follows: Malmö study (13,14), Canadian study II (15–17), Swedish Two-County study (18–24), Stockholm study (25,26), Göteborg study (27,28) and UK Age trial (29). Three RCTs for mammographic screening with clinical breast examination were also identified as follows: New York HIP study (30), Edinburgh study (31) and Canadian study I (32,33). The RCTs which evaluated mortality reduction from breast cancer were limited to eight studies worldwide. Although there were several problems in these studies, we adopted all the RCTs to resolve the primary issues for Japanese women. Canadian studies consisted of two groups with different targets: women aged 50–59 years for Canadian study II (15–17), and women aged 40–49 years for Canadian study I (32,33). In Canadian study II, the screening method for the intervention group was mammography with clinical breast examination; clinical breast examination was also provided for the control group with the same frequency as that for the intervention group (15–17). In Canadian study I, the screening method for the intervention group was mammography with clinical breast examination; clinical breast examination was provided for the control group only at the first screening (32). Based on the inclusion criteria related to a comparator, Canadian study II was excluded from the evidence of mammography without clinical breast examination, and Canadian study I was included as the evidence of mammography with clinical breast examination. From April 2012 to December 2014, although the revised results were reported in a Canadian study, there were no additional studies evaluating mortality reduction from breast cancer (17).

Although two case–control studies evaluating mortality reduction from breast cancer were found for clinical breast examination, there was no study evaluating the effectiveness of ultrasonography for breast cancer.

Body of evidence related to mortality reduction from breast cancer

Mammographic screening without clinical breast examination (level of evidence: 1+)

Five RCTs of mammographic screening without clinical breast examination were identified for mortality reduction from breast cancer (Table 1) (13,14,18–29). The starting years of these studies were around the 1980s except the UK Age trial which commenced in 1991. Randomized allocation was individual-based except the Swedish Two-County study. Although the screening method was the same in these studies, the randomized allocation, target age group, screening interval, radiographic view and follow-up periods were different



Figure 2. Flowchart of literature search. To identify evidence of breast cancer screening in the literature, PubMed, Web of Science, Igaku-Cyuo zasshi and J Dream were searched. A total of 5270 articles were identified from the literature search using PubMed and other databases. After a two-stage review, 110 English articles and 8 Japanese articles were selected.

Table 1. RCTs for evaluation of mammographic screening without clinical breast examination

	Malmö I and II	Swedish Two County	Stockholm	Göteborg	UK Age trial
Starting year of the study	1976	1977	1981	1982	1991
Randomization	Individual	Cluster	Birthday	Birthday	Individual
Number	60 076	133 065 (45)	60 800	52 222	160 921
Target age	45–69 years/43–49 years	38–75 years	39–65 years	39–59 years	39–41 years
Screening method	MMG	MMG + SBE	MMG	MMG	MMG
View	First : two view Subsequent: one view or two view	One view	One view	First: two view Subsequent: one view or two view	First: two view Subsequent: one view or two view
Screening interval (months)	18–24	24 (40s) –33(50s)	24–28	18	12
Screening frequency	6–8	2–4	2	4–5	8–10
Screening periods (years)	12	7	4	7	8
Participation rate (%)	74%	85%	82%	84%	81%
Relative risk (95% CI)	0.81 (0.61–1.07)	0.68 (0.57–0.81)	0.73 (0.50–1.06)	0.75 (0.58–0.97)	0.83 (0.66–1.04)

MMG, mammography; SBE, self-breast examination; CBE, clinical breast examination.
Reference (12).
The relative risk was based on the results of 13 years of follow-up based on the following references: (8) and (16).

(Table 1) (12). Based on the results of the meta-analysis for mammographic screening without clinical breast examination programs, the overall relative risk for all the age groups was 0.75 (95% CI: 0.67–0.83) (Table 2) (12). When the target age group was divided into two groups, the relative risks were 0.81 (95% CI: 0.68–0.96) for women aged 40–49 years and 0.71 (95% CI: 0.62–0.81) for women aged 50–74 years. Since the selected studies covered women aged 40–74 years, the efficacy of mammographic screening could be confirmed for women of this age group.

Mammographic screening with clinical breast examination (level of evidence: 1+)

Three RCTs of mammographic screening with clinical breast examination served as eligible evidence for mortality reduction from breast cancer (Table 3) (17, 30–33). Compared with the studies related to mammographic screening without clinical breast examination, the starting years of these studies were early and detailed information was insufficient. The New York HIP study was the first RCT started in 1963 to evaluate the efficacy of mammographic screening (30). The other studies were commenced at around the 1980s. In the Edinburgh study, inappropriate randomization was suggested because of the different socio-economic classes between the intervention group and the control group (31). Although the screening method was the same in these studies, the control group in Canadian study I was initially provided clinical breast examination (32,33). Three studies were selected to evaluate the efficacy of mammographic screening with clinical breast examination (Table 3). Based on the meta-analysis results, the overall relative risk for all the age groups was 0.87 (95% CI: 0.77–0.98) (Table 2) (12). When the target age group was divided into two groups, the relative risks were 0.87 (95% CI: 0.72–1.04) for women aged 40–49 years and 0.83 (95% CI: 0.70–0.99) for women aged 50–64 years. Since the selected studies covered women aged 40–64 years, the efficacy of mammographic screening could be confirmed for women of this age group.

Clinical breast examination (level of evidence: 2–)

In a previous Japanese study, the odds ratio of mortality reduction from breast cancer for women who have had at least one clinical breast examination within 1 year was 0.93 (95% CI: 0.48–1.79) and that for women who have had clinical breast examination within 5 years was 0.59 (95% CI: 0.48–1.79) (34). However, after excluding symptomatic women, the odds ratio for women who have had at least one clinical breast examination within 1 year was 0.56 (95% CI: 0.27–1.18) and that for women who have had clinical breast examination within 5 year was 0.45 (95% CI: 0.22–0.89). In a case–control study conducted in the USA, the odds ratio of mortality reduction from breast cancer for average-risk women who have had one clinical breast examination within 3 years was 0.94 (95% CI: 0.79–1.12) and that for high-risk women was 0.80 (95% CI: 0.59–1.08) (35). Similar odds ratios were obtained for mammographic screening in this study.

Although RCTs has been mainly conducted in some developing countries, intermediate results have been reported. In these studies, screening was provided annually and interval cancers were identified from follow-up studies and cancer registries. A study in India reported a sensitivity of 51.7% (95% CI: 38.2–65.0) and a specificity of 94.3% (95% CI: 94.1–94.5) for clinical breast examination (36). A study based on the Breast and Cervical Early Detection Program reported a sensitivity of 58.8% and a specificity of 93.4% (37). In the results of a meta-analysis that included an HIP New York study and a Canadian study, the sensitivity was 54.1% (38). Japanese studies reported similar results based on local cancer registries and the sensitivity was different among local areas (39–41). Since clinical breast cancer examination has been performed annually, interval cancer was defined as negative results at the first screening and diagnosed until the next year screening. In a study in Yamagata, Japan, Shibata et al. (39) reported a sensitivity of 46.6% (95% CI: 33.3–60.1) and a specificity of 97.3%. In a study in Miyagi, Japan, the differences in the sensitivities among the target age groups were as follows: 62.4% for women in their 40s, 59.1% for women in their 50s and 59.9% for women their 60s (40). However, the sensitivity was lower in a study conducted in Tochigi, Japan than in other studies based on follow-up using a local cancer registry (41). Based on these studies, although there was a difference among individual skills, clinical breast examination shows a sensitivity of 50% and a specificity of 95% and over.

There are only two studies that have evaluated mortality reduction from breast cancer and their study designs were case–control studies. In addition, the results of these studies were not same. Because of inconsistent results, a definitive confirmation as to whether or not clinical breast examination could reduce mortality from breast cancer could not be made

Table 2. Meta-analysis of mammographic screening with and without clinical breast examination

	Target age group of RCTs	Relative risk (95% CI)			Attribute risk difference (95% CI)		
		All age	40–49 years	≥50 years	All age	40–49 years	≥50 years
Mammography	40–74 years	0.75 (0.67–0.83)	0.81 (0.68–0.96)	0.71 (0.62–0.81)	−0.0010 (−0.0013– −0.0006)	−0.0005 (−0.0009– −0.0001)	−0.0015 (−0.0009– −0.0021)
Mammography with clinical breast examination	40–64 years	0.87 (0.77–0.98)	0.87 (0.72–1.04)	0.83 (0.70–0.99)	−0.0009 (−0.0016– −0.0001)	−0.0007 (−0.0015– −0.0002)	−0.0014 (−0.0027– −5.36E-5)

RCT, randomized controlled trial; CI, confidence interval.

Ultrasonography with and without mammography (level of evidence: 3)
Based on the results of systematic review, there is still no study evaluating mortality reduction from breast cancer using ultrasonography with and without mammography. Although several studies have reported on test accuracy, the sensitivity of ultrasonography was always higher in studies performed in Japan than in studies conducted in western countries (41–44). In a study conducted in Tochigi, Japan, the sensitivity was 53.8% and the specificity was 95.4% based on follow-up using a local cancer registry (41).

Harms of mammographic screening

The major harms of mammographic screening were radiation exposure, false-positive cases, and overdiagnosis (3–7). The risk of radiation exposure was calculated by modeling and this predicted the incidence and mortality of radiation-induced cancer (45–52).

False-positive cases

False-positive cases results in unnecessary diagnostic examinations and occasionally produce psychological effects including anxiety, fear and depression (53–61). Although cumulative false-positive rates were reported in several studies using the modeling approach, the results varied (62–66). In a US study using mammographic screening alone, the reported 10-year cumulative rates for biannual screening were 41.6% (95% CI: 40.6–42.5) for women who started cancer screening from 40 years of age and 42.0% (95% CI: 40.4–43.7) for women who started cancer screening from 50 years of age (63). Although there was no study which predicted the cumulative false-positive rate in Japan, the study in Tochigi, Japan reported a false-positive rate of 7.9% (41).

Despite the similar false-positive rates in the USA and Japan, the invasive biopsy rates for all age groups were lower in Japan (67).

Overdiagnosis

Although there is agreement regarding the basic concept of overdiagnosis, a method of estimating the rate of overdiagnosis has not been standardized to date (5). Therefore, the reported rates of overdiagnosis ranged from 5 to 50% and over (68–82). Pulti et al. (83) reviewed observational studies that provided an estimate of the rate of overdiagnosis in European countries, and reported a range of 1–10%. Although studies on calculating overdiagnosis are still lacking, the reported excess rate of mammographic screening was 141% (69). This rate included overdiagnosis cases, but early cancers that had the possibility of progressing into invasive cancers were also included.

The most reliable estimates of overdiagnosis come from RCTs. In the Malmö study, the rate of overdiagnosis was 10% based on 15 years of follow-up (82). A Canadian study reported an overdiagnosis rate of 22% based on 25 years of follow-up (17). An independent UK panel estimated the rate of overdiagnosis using four types of denominator based on the results of the Malmö study and Canadian studies (5). The panel considered that the data included overdiagnosis in the range of 5–15% from the population perspective and 15–25% from the individual woman's perspective.

Balance of benefits and harms of mammographic screening

The NNI and the number needed for diagnostic examination to avoid one breast cancer death were calculated for mammographic screening with and without clinical breast examination for women aged 40–70 years (Table 4) (12). The NNI was consistently lower in mammographic screening without clinical breast examination than in

Table 3. RCTs for evaluation of mammographic screening with physical examination

	New York HIP	Canada I	Edinburgh
Starting year of the study	1963	1980	1978
Randomization	Individual	Individual	Cluster
Subjects			
Number	62 000	89 835	54 654
Target age	40–64 years	40–49 years	45–64 years
Screening method	MMG + CBE	MMG + CBE + SBE	MMG + CBE
Mammography			
View	Two view	Two view	First: two view Subsequent: one view or two view
Screening interval (months)	12	12	24
Screening frequency	4	4–5	2–4
Screening periods (years)	3	5	6
Participation rate (%)	65%	88%	65%
Relative risk (95% CI)	0.83 (0.70–0.99)	0.97 (0.74–1.27)	0.85 (0.68–1.05)

Reference (12).
The relative risk was based on the results of 13 years of follow-up for the NY HIP study and Canada I study, and 14 years of follow-up for the Edinburgh study.
References (9) and (31).

Table 4. Comparison of benefits and harms between mammographic screening with and without clinical breast examination

Screening method		Target age						
		40 years	45 years	50 years	55 years	60 years	65 years	70 years
Mammographic screening without clinical breast examination	Per 1000 women screened							
	Number of recall	77	77	67	67	53	53	53
	Per single death prevented							
	Number needed to invite	2530	1713	864	777	782	807	833
	Number of recall	195	132	58	52	41	43	44
Mammographic screening with CBE	Per 1000 women screened							
	Number of recall	99	99	76	76	62	62	62
	Per single death prevented							
	Number needed to invite	3698	2504	1474	1325	1334	1376	1420
	Number of recall	366	248	112	101	83	85	88

Number needed to invite are expressed per thousand women invited for 13 years of follow-up.
CBE, clinical breast examination.
Reference (12).

Table 5. Recommendation of breast cancer screening

Screening method	Recommendation grade	Target age group	Recommendations language	
			Population-based screening	Opportunistic screening
Mammography	B	40–74 years	Recommend	Recommend
Mammography with clinical breast examination	B	40–64 years	Recommend	Recommend
Clinical breast examination (alone)	I		Not recommend[a]	Decision-making at the individual[b]
Ultrasonography with and without mammography	I		Not recommend[a]	Decision-making at the individual[b]

[a]There is insufficient evidence to recommend for or against.
[b]If required, the health professional should explain that the evidence regarding mortality and incidence reduction by cancer screening is unclear. In addition, information about the harms is required. In such situations, the decision regarding cancer screening should be made at the individual level.

mammographic screening with clinical breast examination. In both screening methods, the NNI was higher in women aged 40 years than in women aged 50–70 years. Similar results were obtained for the number needed for recall of diagnostic examination to avoid one breast cancer death. These results suggest that mammographic screening without clinical breast examination could provide higher benefits for women aged 50 years and over.

Discussion

In the Japanese guidelines, evidence pointing to the efficacy of mammographic screening with and without clinical breast examination was confirmed. In Japan, the combination method of mammography and clinical breast examination has been performed as the recommended procedure for breast cancer screening. Although mammographic screening without clinical breast examination has not been

recommended in Japan, this procedure is the standard method for breast cancer screening in the USA and European countries (5). With the dissemination of only mammographic units, mammography alone has been anticipated to be introduced in Japanese communities because of the lack of physicians who can correctly perform clinical breast examination. The efficacy of mammography alone could be identified from the results of meta-analysis, and its impact was found to be higher than in the combination method of mammography and clinical breast examination (12). Since the accuracy of mammographic units has been continuously improved, mammography can therefore be used individually without clinical breast examination. In fact, the number of recall to avoid one breast cancer death was lower in mammography alone than in mammography with clinical breast examination (12). Based on the balance of benefits and harms, mammographic screening with and without clinical breast examination is recommended. In addition to improving the screening methods, more opportunities to improve access to mammographic screening in local municipalities should be provided.

However, the original issue remains as to whether Japanese women in their 40s should be included in the target group for mammographic screening. Although most RCTs have included women in their 40s in the target age group, it is insufficient to evaluate the efficacy of mammographic screening according to individual studies except the UK Age trial which targeted women in their 40s. The results of our meta-analysis to clarify the efficacy of mammographic screening without clinical breast cancer screening suggested a 19% mortality reduction from breast cancer (0.81, 95% CI; 0.68–0.96) (12). However, there were gaps in the number needed to invite women to avoid one death from breast cancer and the number needed to recall women to avoid one death from breast cancer between women in their 40s and 50s and above. The net benefits were smaller in women in their 40s than in women in their 50s and above. Ideally, it is preferable to make a recommendation based on evidence evaluated from the guideline developers' own countries because evidence obtained in other countries might not be adopted into other ethnic groups. As there are no RCTs and observational studies evaluating the efficacy and effectiveness of mammographic screening in Japan, a comprehensive assessment of the actual impact of mammographic screening in Japan could not be made. Nevertheless, despite the limited net benefits, we recommend mammographic screening with and without clinical breast examination considering the higher incidence of breast cancer in women in their 40s in Japan.

Although the peak incidence of breast cancer was observed in women aged 40–49 years (1), the sensitivity of mammography was lower in women in their 40s than in women in their 50s and above because of their dense breast (40). However, even if clinical breast examination is added in mammography, the sensitivity cannot always be improved owing to the technical gaps among physicians who have experience and physicians who have no experience. Ultrasonography has been shown to have a higher sensitivity than clinical breast examination (41), and it can detect small tumors in a dense breast without radiation exposure. To increase the magnitude of mortality reduction from breast cancer screening for women aged in their 40s, evaluation of the efficacy of mammographic screening with ultrasonography has been started (84). However, studies conducted in the US have reported a not so high sensitivity as well as the possibility of an increased false-positive rate (7,43,44). As studies evaluating mortality reduction from breast cancer by ultrasonography with and without mammography remain lacking, we could not accurately evaluate whether or not ultrasonography can be an alternative method for clinical breast examination.

To date, mammographic screening has been widely recommended and implemented in developed countries (5). In fact, most guidelines recommend mammographic screening for women aged 50–69 years every 2 or 3 years (3–7). Although the efficacy of mammographic screening has been evaluated by RCTs, there has been a long discussion regarding its efficacy since the publication of the Cochrane review in 2000. In the Cochrane review, questions about the efficacy of mammographic screening and the imbalance of benefits and harms have been raised (9). Moreover, the unconfirmed estimation method adds another layer of confusion in the evaluation of the net benefits of mammographic screening (5). Since the net benefits might be decreased in cases of overestimation, the range of overdiagnosis showed a large variation from 5 to 50% (68–84). In most influential guidelines and evidence reports, the efficacy of mammographic screening was re-evaluated on the basis of the results of RCTs and was reconfirmed. However, with much weight placed on the results of the Cochrane review, mammographic screening has not been recommended in some guidelines such as those of the Swiss Medical Association (10). For guidelines development, although the balance of benefits and harms based on valid evidence is a priority issue, the overall background should also be considered (85). To identify and confirm the best available method for breast cancer screening in Japan, original studies evaluating the actual impact of mammographic screening are warranted. We aim to revise and further improve the Japanese guidelines for breast cancer screening based on the results of new research studies after 5 years.

Recommendations

Based on the balance of benefits and harms, recommendations were formulated for population-based and opportunistic screenings (Table 5). Benefits were defined as evidence that mortality from a specific cancer was reduced by a cancer screening program.

Mammographic screening without clinical breast examination for women aged 40–74 years is recommended for population-based and opportunistic screenings as its benefits outweighs its harms (*Recommendation grade B*). Mammographic screening with clinical breast examination for women aged 40–64 years is recommended for population-based and opportunistic screenings as its benefit outweighs its harms (*Recommendation grade B*). As there remains insufficient evidence of mortality reduction from breast cancer, clinical breast examination and ultrasonography are not recommended for population-based screening (*Recommendation grade I*). With respect to opportunistic screening, if individuals request these screenings, they should be given appropriate information with the decision made at the individual level.

Acknowledgements

We are grateful to Dr Edward F. Barroga, Associate Professor and Senior Medical Editor of Tokyo Medical University for the editorial review of the manuscript. We also thank Ms Kanoko Matsushima, Ms Junko Asai and Ms Hiromi Sugiyama for research assistance.

Funding

This study was supported by the National Cancer Center, Tokyo, Japan (grant number: 26-A-30).

Conflict of interest statement

None declared.

References

1. Center for Cancer Control and Information Services, National Cancer Center [Internet]. Japan: (updated 15 December 2015) Available from: http://ganjoho.jp/reg_stat/statistics/index.html.
2. International Agency for Research on Cancer. Chapter 3. Use of breast cancer screening. In: Harri V, Franca B, editors. *IARC Handbooks on Cancer Prevention Volume 7. Breast cancer screening*. Lyon: IARC press 2002;47–86.
3. International Agency for Research on Cancer [Internet]. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. [updated 2012] Available from http://globocan.iarc.fr/.
4. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. *Ann Intern Med* 2009;151:727–37.
5. The Canadian Task Force on Preventive Health Care. Recommendations on screening for breast cancer in average-risk women aged 40–74 years. *CMAJ* 2011;183:1991–2001.
6. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. *Br J Cancer* 2013;108:2205–40.
7. Lauby-Secretan B, Scoccianti C, Loomis D, et al. International Agency for Research on Cancer Handbook Working Group. Breast-cancer screening-viewpoint of the IARC Working Group. *N Engl J Med* 2015;372:2353–8.
8. Hisamichi S, editor. *Guidelines for cancer screening programs*. Tokyo: Japan Public Health Association; 2001. (in Japanese).
9. Gøtzsche PC, Jorgensen KJ. Screening for breast cancer with mammography. *Cochrane Database Syst Rev* 2013;6:CD001877.
10. Biller-Andorno N, Jüni P. Abolishing mammography screening programs? A View from the Swiss Medical Board. *N Engl J Med* 2014;370:1965–7.
11. Hamashima C, Saito H, Nakayama T, Nakayama T, Sobue T. The standardized development method of the Japanese guidelines for cancer screening. *Jp J Clin Oncol* 2008;38:288–95.
12. Hamashima C, Ohta K, Kasahara Y, et al. A meta-analysis of mammographic screening with and without clinical breast examination. *Cancer Sci* 2015;106:812–8.
13. Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: updated results from the Malmö Mammographic Screening Program. *J Natl Cancer Inst Monogr* 1997;22:63–7.
14. Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomized trials. *Lancet* 2002;359:909–19.
15. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. *CMAJ* 1992;147:1477–88.
16. Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50–59 years. *J Natl Cancer Inst* 2000;92:1490–9.
17. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomized screening trial. *BMJ* 2014;348:g366.
18. Tabar L, Fagerberg G, Chen HH, et al. Efficacy of breast-cancer screening by age—new results from the Swedish Two-County Trial. *Cancer* 1995;75:2507–17.
19. Tabár L, Fagerberg CJ, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomized trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. *Lancet* 1985;1:829–32.
20. Duffy SW, Tabar L, Vitak B, et al. The Swedish Two-County Trial of mammographic screening: cluster randomization and end point evaluation. *Ann Oncol* 2003;14:1196–8.
21. Tabar L, Vitak B, Chen HH, Prevost TC, Duffy SW. Update of the Swedish Two-County Trial of breast cancer screening: histologic grade-specific and age-specific results. *Swiss Surg* 1999;5:199–204.
22. Tabar L, Duffy SW, Yen MF, et al. All-cause mortality among breast cancer patients in a screening trial: support for breast cancer mortality as an end point. *J Med Screen* 2002;9:159–62.
23. Tabár L, Vitak B, Chen HH, Yen MF, Duffy SW, Smith RA. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. *Cancer* 2001;91:1724–31.
24. Duffy SW, Tabar L, Olsen AH, et al. Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England. *J Med Screen* 2010;17:25–30.
25. Frisell J, Eklund G, Hailstorm L, Lidbrink E, Rutqvist LE, Somell A. Randomized study of mammography screening-preliminary report on mortality in the Stockholm trial. *Breast Cancer Res Treat* 1991;18:49–56.
26. Frisell J, Lidbrink E, Hellström L, Rutqvist LE. Follow-up after 11 years—update of mortality results in the Stockholm mammographic screening trial. *Breast Cancer Res Treat* 1997;45:263–70.
27. Bjurstam N, Björneld L, Duffy SW, et al. The Gothenburg Breast Screening Trial—first results on mortality, incidence, and mode of detection for women ages 39–49 years at randomization. *Cancer* 1997;80:2091–9.
28. Bjurstam N, Björneld L, Warwick J, et al. The Gothenburg Breast Screening Trial. *Cancer* 2003;97:2387–96.
29. Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L. Trial Management Group. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomized controlled trial. *Lancet* 2006;368:2053–60.
30. Habbema JD, van Oortmarssen GJ, van Putten DJ, Lubbe JT, van der Maas PJ. Age-specific reduction in breast cancer mortality by screening: an analysis of the results of the Health Insurance Plan of Greater New York study. *J Natl Cancer Inst* 1986;77:317–20.
31. Alexander FE, Anderson TJ, Brown HK, et al. 14 years of follow-up from the Edinburgh randomized trial of breast-cancer screening. *Lancet* 1999;353:1903–8.
32. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. *CMAJ* 1992;147:1459–76.
33. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. *Ann Intern Med* 2002;137:305–12.
34. Kanemura S, Tsuji I, Ohuchi N, et al. A case control study on the effectiveness of breast cancer screening by clinical breast examination in Japan. *Jpn J Cancer Res* 1999;90:607–13.
35. Elmore JG, Reisch LM, Barton MB, et al. Efficacy of breast cancer screening in the community according to risk level. *J Natl Cancer Inst* 2005;97:1035–43.
36. Sankaranarayanan R, Ramadas K, Thara S, et al. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. *J Natl Cancer Inst* 2011;103:1476–80.
37. Bobo JK, Lee NC, Thames SF. Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. *J Natl Cancer Inst* 2000;92:971–6.
38. Barton MB, Harris R, Fletcher SW. The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? *JAMA* 1999;282:1270–80.
39. Shibata A, Takahashi T, Ouchi N, Fukao A. Evaluation of service screening for breast cancer by clinical breast examination using regional cancer registry data. *Jpn J Public Health* 2005;52:128–36.
40. Suzuki A, Kuriyama S, Kawai M, et al. Age-specific interval breast cancers in Japan: estimation of the proper sensitivity of screening using a population-based cancer registry. *Cancer Sci* 2008;99:2264–7.
41. Honjo S, Ando J, Tsukioka T, et al. Relative and combined performance of mammography and ultrasonography for breast cancer screening in the general population: a pilot study in Tochigi Prefecture, Japan. *Jpn J Clin Oncol* 2007;37:715–20.
42. Uchida K, Yamashita A, Kawase K, Kamiya K. Screening ultrasonography revealed 15% of mammographically occult breast cancers. *Breast Cancer* 2008;15:165–8.

43. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. *Radiology* 2002;225:165–75.
44. Berg WA, Blume JD, Cormack JB, et al.; ACRIN 6666 Investigators. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. *JAMA* 2008;299:2151–63.
45. Bijwaard H, Brenner A, Dekkers F, van Dillen T, Land CE, Boice JD Jr. Breast cancer risk from different mammography screening practices. *Radiat Res* 2010;174:367–76.
46. Beemsterboer PM, Warmerdam PG, Boer R, de Koning HJ. Radiation risk of mammography related to benefit in screening programmes: a favorable balance? *J Med Screen* 1998;5:81–7.
47. Beckett JR, Kotre CJ, Michaelson JS. Analysis of benefit-risk ratio and mortality reduction for the UK Breast Screening Programme. *Br J Radiol* 2003;76:309–20.
48. Yaffe MJ, Mainprize JG. Risk of radiation-induced breast cancer from mammographic screening. *Radiology* 2011;258:98–105.
49. Mattsson A, Leitz W, Rutqvist LE. Radiation risk and mammographic screening of women from 40 to 49 years of age: effect on breast cancer rates and years of life. *Br J Cancer* 2000;82:220–6.
50. León A, Verdú G, Cuevas MD, Salas MD, Villaescusa JI, Bueno F. Study of radiation induced cancers in a breast screening programme. *Radiat Prot Dosimetry* 2001;93:19–30.
51. Berrington de González A, Reeves G. Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits. *Br J Cancer* 2005;93:590–6.
52. Ramos M, Ferrer S, Villaescusa JI, Verdú G, Salas MD, Cuevas MD. Use of risk projection models to estimate mortality and incidence from radiation-induced breast cancer in screening programs. *Phys Med Biol* 2005;50:505–20.
53. Brewer NT, Salz T, Lillie SE. Systematic review: the long-term effects of false-positive mammograms. *Ann Intern Med* 2007;146:502–10.
54. Gibson CJ, Weiss J, Goodrich M, Onega T. False-positive mammography and depressed mood in a screening population: findings from the New Hampshire Mammography Network. *J Public Health (Oxf)* 2009;31:554–60.
55. Lindfors KK, O'Connor J, Parker RA. False-positive screening mammograms: effect of immediate versus later work-up on patient stress. *Radiology* 2001;218:247–53.
56. Scaf-Klomp W, Sanderman R, van de Wiel HB, Otter R, van den Heuvel WJ. Distressed or relieved? Psychological side effects of breast cancer screening in The Netherlands. *J Epidemiol Community Health* 1997;51:705–10.
57. Sandin B, Chorot P, Valiente RM, Lostao L, Santed MA. Adverse psychological effects in women attending a second-stage breast cancer screening. *J Psychosom Res* 2002;52:303–9.
58. van der Steeg AF, Keyzer-Dekker CM, De Vries J, Roukema JA. Effect of abnormal screening mammogram on quality of life. *Br J Surg* 2011;98:537–42.
59. Lampic C, Thurfjell E, Bergh J, Sjödén PO. Short- and long-term anxiety and depression in women recalled after breast cancer screening. *Eur J Cancer* 2001;37:463–9.
60. Andersen SB, Vejborg I, von Euler-Chelpin M. Participation behaviour following a false positive test in the Copenhagen mammography screening programme. *Acta Oncol* 2008;47:550–5.
61. Brett J, Austoker J, Ong G. Do women who undergo further investigation for breast screening suffer adverse psychological consequences? A multicentre follow-up study comparing different breast screening result groups five months after their last breast screening appointment. *J Public Health Med* 1998;20:396–403.
62. Castells X, Molins E, Macià F. Cumulative false positive recall rate and association with participant related factors in a population based breast cancer screening programme. *J Epidemiol Community Health* 2006;60:316–21.
63. Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. *Ann Intern Med* 2011;155:481–92.
64. Salas D, Ibáñez J, Román R, et al. CFPR (Cumulative False Positive Risk) group. Effect of start age of breast cancer screening mammography on the risk of false-positive results. *Prev Med* 2011;53:76–81.
65. Hofvind S, Thoresen S, Tretli S. The cumulative risk of a false-positive recall in the Norwegian Breast Cancer Screening Program. *Cancer* 2004;101:1501–7.
66. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. *N Engl J Med* 1998;338:1089–96.
67. Kasahara Y, Tsuji I, Ichimura M, et al. Annual Report 2011 on Breast Cancer Screening in Japan. *J Jpn Assoc Breast Cancer Screening* 2012;21:48–58.
68. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. *N Engl J Med* 2012;367:1998–2005.
69. Hamashima C, Sobue T, Muramatsu Y, Saito H, Moriyama N, Kakizoe T. Comparison of observed and expected numbers of detected cancers in the research center for cancer prevention and screening program. *Jpn J Clin Oncol* 2006;36:301–8.
70. Jørgensen KJ, Zahl PH, Gøtzsche PC. Overdiagnosis in organized mammography screening in Denmark. A comparative study. *BMC Women's Health* 2009;9:36.
71. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organized mammography screening programmes: systematic review of incidence trends. *BMJ* 2009;339:b2587.
72. Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. *BMJ* 2004;328:921–4.
73. Puliti D, Zappa M, Miccinesi G, Falini P, Crocetti E, Paci E. An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence. *Eur J Cancer* 2009;45:3166–71.
74. Paci E, Miccinesi G, Puliti D, et al. Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy. *Breast Cancer Res* 2006;8:R68.
75. de Gelder R, Heijnsdijk EA, van Ravesteyn NT, Fracheboud J, Draisma G, de Koning HJ. Interpreting overdiagnosis estimates in population-based mammography screening. *Epidemiol Rev* 2011;33:111–21.
76. Morrell S, Barratt A, Irwig L, Howard K, Biesheuvel C, Armstrong B. Estimates of overdiagnosis of invasive breast cancer associated with screening mammography. *Cancer Causes Control* 2010;21:275–82.
77. Seigneurin A, François O, Labarère J, Oudeville P, Monlong J, Colonna M. Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. *BMJ* 2011;343:d7017.
78. Junod B, Zahl PH, Kaplan RM, Olsen J, Greenland S. An investigation of the apparent breast cancer epidemic in France: screening and incidence trends in birth cohorts. *BMC Cancer* 2011;11:401.
79. de Gelder R, Fracheboud J, Heijnsdijk EA, et al. Digital mammography screening: Weighing reduced mortality against increased overdiagnosis. *Prev Med* 2011;53:134–40.
80. Yen MF, Tabár L, Vitak B, Smith RA, Chen HH, Duffy SW. Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. *Eur J Cancer* 2003;39:1746–54.
81. Olsen AH, Agbaje OF, Myles JP, Lynge E, Duffy SW. Overdiagnosis, sojourn time, and sensitivity in the Copenhagen mammography screening program. *Breast J* 2006;12:338–42.
82. Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of overdiagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study. *BMJ* 2006;332:689–91.
83. Puliti D, Duffy SW, Miccinesi G, et al. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. *Med Screen September* 2012;19:42–56.
84. Ishida T, Suzuki A, Kawai M, et al. A randomized controlled trial to verify the efficacy of the use of ultrasonography in breast cancer screening aged 40–49 (J-START): 76 196 women registered. *Jpn J Clin Oncol* 2014;44:134–40.
85. Schünemann HJ, Fretheim A, Oxman AD. Improving the use of research evidence in guideline development: 10: Integrating values and consumer involvement. *Health Res Policy Syst* 2006;4:22.

Appendix

Japanese Research Group for Development of Breast Cancer Screening Guidelines

Chisato Hamashima C (National Cancer Center), Masakazu Hattori (Fukui Prefecture Hospital), Satoshi Honjo (National Hospital Organization Fukuoka National Hospital), Yoshio Kasahara (Fukui-ken Saiseikai Hospital), Takafumi Katayama (University of Hyogo), Masahiro Nakai (Mie Prefecture Health Management Center Clinic), Tomio Nakayama (Osaka Medical Center for Cancer and Cardiovascular Diseases), Takako Morita (National Hospital Organization Nagoya Medical Center), Koji Ohta (Fukui Prefecture Hospital), Koji Ohnuki (Iwate Prefectural Central Hospital), Motoyasu Sagawa (Kanazawa Medical University), Hiroshi Saito (National Cancer Center), Seiju Sasaki (St. Luke's International Hospital), Tomoyuki Shimada (Hiraka Hospital), Tomotaka Sobue (Osaka University), Akihiko Suto (St. Marianna University).

Qual Life Res (2016) 25:707–719
DOI 10.1007/s11136-015-1108-2

Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D

Takeru Shiroiwa[1] · Takashi Fukuda[1] · Shunya Ikeda[2] · Ataru Igarashi[3] · Shinichi Noto[4] · Shinya Saito[5] · Kojiro Shimozuma[6]

Accepted: 17 August 2015 / Published online: 25 August 2015

Abstract
Purpose The purpose of this study was to measure the population norms for the Japanese versions of preference-based measures (EQ-5D-3L, EQ-5D-5L, and SF-6D). We also considered the relations between QOL score in the general population and socio-demographic factors.
Methods A total of 1143 adult respondents (aged ≥ 20 years) were randomly sampled from across Japan using data from the Basic Resident Register. The health status of each respondent was measured using the EQ-5D-3L, EQ-5D-5L, and SF-6D, and responses regarding socio-demographic data as well as subjective diseases and symptoms were obtained. The responses were converted to a QOL score using Japanese value sets.
Results The percentages of respondents with full health scores were 68 % (EQ-5D-3L), 55 % (EQ-5D-5L), and 4 % (SF-6D). The QOL score measured using the SF-6D was significantly lower than those measured using either EQ-5D score. The QOL score was significantly lower among respondents over the age of 60 years, those who had a lower income, and those who had a shorter period of education. Intraclass correlation coefficient showed a poor agreement between the EQ-5D and SF-6D scores. The differences in QOL scores between respondents with and those without any disease were 0.064 for the EQ-5D-3L, 0.061 for the EQ-5D-5L, and 0.073 for the SF-6D; these differences are regarded as between-group minimal important differences in the general population.
Conclusion The Japanese population norms of three preference-based QOL measures were examined for the first time. Such information is useful for economic evaluations and research examining QOL score.

Keywords EQ-5D · SF-6D · Health-related quality of life · Population norms · QALY · Japan

✉ Takeru Shiroiwa
t.shiroiwa@gmail.com

[1] Department of Health and Welfare Services, National Institute of Public Health, 2-3-6 Minami, Wako, Saitama 351-0197, Japan

[2] School of Pharmacy, International University of Health and Welfare, Otawara, Japan

[3] Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan

[4] Department of Health Sciences, Niigata University of Health and Welfare, Niigata, Japan

[5] Graduate School of Health Sciences, Okayama University, Okayama, Japan

[6] Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Kyoto, Japan

Introduction

When economic evaluations of healthcare technologies are performed, the incremental cost-effectiveness ratio (ICER) is regarded as a standard calculation. Various outcomes can be used as the denominator of ICER, but quality-adjusted life year (QALY) is widely applied for various areas of cost-effectiveness analysis. One reason is that quality of life (QOL) is one of the most important outcomes for not only medical interventions, but also healthcare policies. To calculate the QALY, the QOL score must be measured on a scale of 0 (death) to 1 (full health). Preference-based measures, such as the EuroQol 5-dimension (EQ-5D) [1, 2], the Health Utilities Index (HUI) [3–5], and the Short Form 6-dimension (SF-6D) [6–8], have been developed to calculate QOL scores. These measures were originally

developed in English but have been translated into many languages. Japanese value sets for the EQ-5D (3L [9] and 5L [10]) and the SF-6D [11] have also been developed.

The mean QOL score in the general population is normally <1 because some people will have a less than full health score. People with diseases or symptoms are likely to continue living in their local community. Others may not report their health state as full health even if they do not have any diseases. Such reductions in QOL should be reflected in QALY calculations for economic evaluations. In addition, to interpret QOL scores obtained through a survey, it is important to be compared with the score for the general population as a reference value. Therefore, the *population norms*, which have been previously defined as "population reference data… for a specific country or international region" [12], used for preference-based measures are essential for both researchers and policy-makers. The norms for these measures, especially for the EQ-5D-3L, have already been reported in many countries, including the UK [13], USA [14, 15], six European countries (Belgium, France, Germany, Italy, Netherlands and Spain) [16, 17], Spain (Catalonia) [18], Switzerland (French-speaking population) [19], Finland [20], Denmark [21], Portugal [22], Poland [23], Canada (Alberta) [24], Australia (Queensland) [25], China [26], Taiwan [27], Singapore [28, 29], Sri Lanka [30], and Brazil [31]. The population norms for the SF-6D have also been investigated in some countries, including the UK [32], USA [15], Australia [33], Portugal [34], and Brazil [35]. However, the Japanese population norms for QOL scores do not currently exist, with the exception of surveys performed in three areas [12] that were originally performed to obtain a value set [9]. Few standard norms for the EQ-5D-5L, a newly developed measure by the EuroQol Group, have been reported across the world.

The population in Japan was about 12.5 million in 2015, and almost all of the population speaks Japanese. Therefore, Japanese versions of the EQ-5D-3L, EQ-5D-5L, and SF-6D are widely used for calculating QOL scores in Japan, and Japan's economic evaluation guideline [36] recommends the use of measures with value sets developed in Japan. The Ministry of Health, Labour and Welfare (MHLW) of Japan has collected data on these measures based on our concept. They also collected responses to a questionnaire included in the National Livelihood Survey, which Japan's MHLW performs annually. This questionnaire includes questions regarding disease types and subjective symptoms.

Therefore, the objective of this study was to analyze data to obtain the population norms for the Japanese versions of three preference-based measures: the EQ-5D-3L, EQ-5D-5L, and SF-6D. The second objective was to examine the characteristics of each measure and the relations among measures. We also aimed to present the relation between the QOL score for the general population and characteristics such as sex, age, diseases, symptoms, and other socio-demographic factors.

Methods

Sampling

Data in this study came from MHLW's survey, which took a representative sample. In the survey, a total of 1000 adult respondents (aged ≥ 20 years) were targeted in a random sampling from 100 sites (municipalities). The method used to select the 100 sites was as follows: First, the number of sites in each region (8 regions) was determined in proportion to the population of each region. Then, in every region, the number of sites belonging to each stratum (prefecture × size of municipalities) was calculated based on the populations of the stratum. The surveyed district (Cho-me, in Japanese) was randomly determined in a manner corresponding to the allocated number of sites in each stratum. Respondents were also randomly sampled from each selected district, stratified according to sex and age. People in a hospital or a nursing home were not included.

The Basic Resident Register can be used to select respondents living on each street in a random manner. In Japan, each municipality has its own Basic Resident Register data, which includes information on the name, sex, address, and date of birth of all residents. Each municipality has permitted the use of such data for public surveys. A door-to-door survey was performed from January to March in 2013. Investigators visited the registered addresses and distributed the questionnaire. They then collected the questionnaires a few days later and checked for any apparent errors (placement method). These visits continued until the planned number of responses was collected for each district. The investigators obtained the informed consent of all the respondents.

Measures

Health status was measured using the EQ-5D-3L, EQ-5D-5L, and SF-6D. The respondents were presented with the EQ-5D-5L, EQ-5D-3L, and SF-6D (SF-36) in a fixed order. In addition, socio-demographic data for the respondents, such as sex, age, education, marital status, employment, and household income, were also collected.

The EQ-5D was developed by the EuroQol Group. The original version of the EQ-5D (now called the EQ-5D-3L) is comprised of five items: "mobility," "self-care," "usual activities," "pain/discomfort," and "anxiety/depression" assessed at three levels of description. To improve the lack of a sufficient sensitivity and the ceiling effect of the EQ-

5D-3L, the newly developed EQ-5D-5L [37] has increased the number of levels for each health dimension from three to five.

The SF-6D is a measure for converting responses to the SF-36 (or SF-12 [38]) to a preference-based QOL score for economic evaluation. The SF-36 [39–41] is the most widely used measure for assessing health states in the world. Responses to selected items of the SF-36 can be classified according to descriptions of the SF-6D system, which consists of six dimensions [physical functioning (PF), role limitation (RL), social functioning (SF), bodily pain (BP), mental health (MH), and vitality (VT)] with five or six levels (defining a total of 22,500 health states). As the direct use of the SF-6D questionnaire is not recommended, we used the Japanese SF-36, version 2 [42].

The questionnaire also included a part of the National Livelihood Survey, which Japan's MHLW performs annually. The questionnaire asks respondents whether they have any diseases for which they consult a doctor or not and whether they have any subjective symptoms or not. If they answer "yes," they must then select the most important diseases and symptoms that they exhibit from a list of forty symptoms (having a fever, feeling sluggish, sleeplessness, etc.) and diseases (diabetes, obesity, hyperlipidemia, etc.).

Statistical analysis

The responses obtained for the EQ-5D-3L, EQ-5D-5L, and SF-6D were first converted to QOL scores based on the Japanese value sets. Summary statistics for the QOL scores were calculated according to sex and age category (20–29, 30–39, 40–49, 50–59, 60–69, and 70 years and older). The percentage of people reporting any problem in each dimension was calculated after stratifying the subjects according to sex and age category. Chi-square tests (or the Fisher exact test if the expected frequency was low) were applied to determine the significance between the frequency of respondents with any problem and sex or age. The McNemar test was performed to confirm the frequencies of respondents with any problem in the EQ-5D-3L and the EQ-5D-5L. The intraclass correlation coefficient (ICC) was used for reliability between the three measures in addition to the Bland–Altman plot [43]. In the Bland–Altman plot, the average of the two measures was plotted on the x-axis, and the difference between the two measurements on the y-axis was used to check for systematic errors.

To detect the influence of socio-demographic factors and diseases/symptoms on the QOL scores, these variables were added (in addition to sex and age) to an analysis of variance (ANOVA). Diseases and symptoms for which more than 10 respondents had responded positively or that had a significant influence on the QOL score were included in the above statistical model. The influence of each disease and symptom was estimated using an ANOVA that included all the pertinent variables. The significance level was set at 0.05. Statistical analyses were performed using SAS 9.4.

We compared the QOL scores of the respondents between those with any subjective diseases/symptoms and those without using an ANOVA model. The difference was interpreted as the between-group minimal important difference (MID) of each preference-based measure in the general population. The MID, which corresponds to the smallest improvement considered to be worthwhile by a patient, is normally measured using a distribution-based or anchor-based method. Reportedly, "anchor-based differences can be determined either cross-sectionally at a single time point or longitudinally across multiple time points" [44]. The former cross-sectional anchor-based method was applied to our data, as the diseases and subjective symptoms were regarded as the anchors for the between-group MID.

This analysis was approved by the Ethics Committee of the National Institute of Public Health.

Results

Socio-demographic factors

Table 1 shows the socio-demographic factors of the sampled respondents. In total, the responses of 1143 respondents were randomly collected. In 2013, 4.3 % of the Japanese population lived in Hokkaido region, 7.1 % lived in Tohoku, 33.5 % lived in Kanto, 16.9 % lived in Chubu, 17.8 % lived in Kinki, 5.9 % lived in Chugoku, 3.1 % lived in Shikoku, and 11.4 % lived in Kyushu. The actual Japanese median household income was JPY 4.3 million, while the average was JPY 5.4 million in 2012. Married and unmarried people accounted for 61.1 and 22.8 % of the population, respectively. Overall, 19.1 % had graduated from university. Note that this statistic reflects the actual distribution of the population, but we sampled the same number of respondents from each age category. This means that the percentage among younger people was higher than that of the entire Japanese population. Based on the responses to the National Livelihood Survey, 48.2 % of the respondents had some disease for which they were consulting a doctor, while 48.6 % had some symptoms.

QOL score and relation to socio-demographic factors

Table 2 shows the mean scores of the EQ-5D-3L, EQ-5D-5L, and SF-6D in the general population classified

Table 1 Socio-demographic characteristics of respondents

	N	%
Age		
20–29	198	17.3
30–39	162	14.2
40–49	183	16.0
50–59	190	16.6
60–69	202	17.7
≥70	208	18.2
Sex		
Male	558	48.8
Female	585	51.2
Region		
Hokkaido	40	3.5
Tohoku	84	7.4
Kanto	383	33.5
Chubu	193	16.9
Kinki	205	17.9
Chugoku	64	5.6
Shikoku	34	3.0
Kyushu	140	12.3
Household income (JPY 10,000)		
<100	42	4.2
100–200	84	8.5
200–400	245	24.7
400–600	232	23.4
600–1000	257	25.9
1000–1500	101	10.2
1500–2000	18	1.8
>2000	13	1.3
Employment		
Full-time worker	429	37.8
Part-time worker	164	14.4
Self-employed or manager	114	10.0
Housemaker	231	20.3
Retired	126	11.1
Others	27	2.4
Education		
Elementary or junior high school	128	11.3
High school	468	41.2
College	237	20.9
University or graduate	291	25.6
Current student	11	1.0
Marital status		
Married	753	66.1
Unmarried	251	22.0
Divorced/bereaved	136	11.9

according to sex and age category. The QOL score measured using the SF-6D was significantly lower than those measured using the EQ-5D scores. The ICC was 0.802 between EQ-5D-3L and EQ-5D-5L, 0.249 between EQ-5D-3L and SF-6D, and 0.234 between EQ-5D-5L and SF-6D, respectively. The Bland–Altman plot between EQ-5D-5L and SF-6D is shown in Fig. 1. This plot indicates that outliers (SF-6D scores that are higher than the EQ-5D scores) exist for lower QOL scores.

In Table 3, the results of the ANOVA, including socio-demographic factors, are presented. The measured QOL scores of people older than 60 years of age were significantly lower than those of younger people when calculated using all three measures. The QOL scores of women tended to be slightly lower than those of men. Considering other socio-demographic factors, a lower household income (<2 million JPY) was associated with a lower QOL score, even after adjustments for sex and age. A shorter education period also influenced the QOL score, but the QOL scores did not differ among people who had received an education beyond high school. Marital status and employment pattern (full time, part time or self-employment) were not correlated with the QOL score.

A comparison with the population norms for the EQ-5D-3L and SF-6D in other countries is shown in Fig. 2. The figure shows the relation between the mean QOL score of both sexes and the median age category based on published reports [EQ-5D-3L (country-specific value set): Szende et al. [12] except Singapore [29], SF-6D: already shown in the Introduction section]. The Japanese population norms for the EQ-5D tended to be lower than those in some countries (China, Korea, Singapore, and Germany) and to be higher than others (USA, UK, France, and Thailand). On the other hand, the SF-6D score was the lowest among the other countries (USA, UK, Australia, Portugal, and Brazil) for which population norms are available.

Percentage of respondents reporting full health

The percentages of respondents reporting full health were 68 % when measured using the EQ-5D-3L (80 % for subjects in their 20 s, 78 % in their 30 s, 75 % in their 40 s, 74 % in their 50 s, 60 % in their 60 s, and 47 % in their 70 s or older) and 55 % when measured using the EQ-5D-5L (70, 64, 55, 59, 47, and 38 % for the respective age categories); however, 4 % (8, 3, 4, 6, 3, and 2 % for the respective age categories) reported full health when measured using the SF-6D (Fig. 3). Table 4 shows the percentages of respondents with any problem in each dimension of the EQ-5D-3L, the EQ-5D-5L, and the SF-

Table 2 Summary statistics of QOL scores

Age (years)	Male			Female		
	EQ-5D-3L	EQ-5D-5L	SF-6D	EQ-5D-3L	EQ-5D-5L	SF-6D
20–29						
N	100	100	95	98	98	98
Mean	0.947	0.945	0.731	0.946	0.950	0.727
SD	0.114	0.102	0.136	0.112	0.084	0.133
30–39						
N	76	76	76	85	86	86
Mean	0.957	0.950	0.729	0.933	0.937	0.695
SD	0.098	0.080	0.125	0.121	0.089	0.114
40–49						
N	88	88	88	95	95	93
Mean	0.948	0.941	0.704	0.917	0.914	0.688
SD	0.129	0.088	0.124	0.134	0.102	0.128
50–59						
N	88	88	87	102	102	98
Mean	0.936	0.936	0.741	0.921	0.928	0.704
SD	0.121	0.101	0.135	0.130	0.092	0.129
60–69						
N	101	101	98	100	101	101
Mean	0.896	0.911	0.691	0.881	0.899	0.658
SD	0.156	0.158	0.141	0.144	0.105	0.112
≥70						
N	105	104	101	103	102	99
Mean	0.853	0.866	0.674	0.808	0.828	0.635
SD	0.164	0.155	0.137	0.202	0.202	0.129



Fig. 1 Bland–Altman plot between EQ-5D-5L and SF-6D

6D. Among younger people's responses for the EQ-5D, the percentages of pain/discomfort and anxiety/depression were higher than those of other dimensions, which mainly correspond to physical and/or social function. When both sexes were compared, the percentage of women with any problem in the pain/discomfort dimension was significantly higher than that for men regardless of age. In addition, the EQ-5D-5L detected more health problems than the 3L in almost all the dimensions independently of the sex and age categories. Respondents chose a not-full state on the SF-6D more frequently than on the EQ-5D. For example, in almost all the sex and age categories, approximately 50–70 % of respondents reported a problem in the pain dimension, 60–80 % in the mental health dimension, and 80–90 % in the vital dimension.

Influence of diseases and symptoms on QOL score

Table 5 shows the relations between the QOL scores and both the diseases and symptoms that the respondents felt were the most important to them. Among the diseases, "depression or mental diseases," "stroke," and "rheumatoid arthritis" had the largest influence on the QOL score. These diseases decreased the QOL by 0.15–0.2. On the other hand, "dyslipidemia," "hypertension," and "tooth disorder" had a minimal impact on the QOL score,

Table 3 Relation between QOL scores and socio-demographic characteristics

	Model 1			Model 2		
	EQ-5D-3L	EQ-5D-5L	SF-6D	EQ-5D-3L	EQ-5D-5L	SF-6D
Intercept	0.9574	0.9551	0.7430	0.8516	0.8434	0.6535
Age (years)						
20–29	–	–	–	–	–	–
30–39	−0.0018	−0.0041	−0.0177	0.0019	−0.0024	−0.0142
40–49	−0.0146	−0.0201	−0.0336*	−0.0205	−0.0236	−0.0353*
50–59	−0.0182	−0.0150	−0.0076	−0.0234	−0.0186	−0.0115
60–69	−0.0581*	−0.0426*	−0.0552*	−0.0566*	−0.0432*	−0.0493*
≥70	−0.1160*	−0.1000*	−0.0752*	−0.0915*	−0.0743*	−0.0618*
Sex						
Male	–	–	–	–	–	–
Female	−0.0218*	−0.0156*	−0.0273*	−0.0211*	−0.0147	−0.0268*
Household income (JPY 10,000)						
<100				–	–	–
100–200				0.0060	0.0269	0.0071
200–400				0.0547*	0.0652*	0.0582*
400–600				0.0616*	0.0731*	0.053488*
600–1000				0.0577*	0.0774*	0.0603*
1000–1500				0.0613*	0.0716*	0.0586*
1500–2000				0.0904*	0.0942*	0.1106*
>2000				0.0934*	0.1095*	0.0747
Education						
Elementary or junior high				–	–	–
High school				0.0531*	0.0499*	0.0402*
College				0.0518*	0.0438*	0.0393*
University or graduate				0.0675*	0.0493*	0.0396*

* P value < 0.05

although their prevalence was relatively high. Considering the prevalence of diseases (decrease in the QOL score multiplied by the number of respondents), "depression or mental diseases," "lumbago," and "diabetes" were the top three diseases, decreasing the QOL score at the general population level. The QOL scores of respondents with some symptoms, such as "sleeplessness," "arthritic pain," and "having trouble moving limbs," were lower than those of respondents reporting other symptoms.

The differences in the QOL scores between respondents with and those without any diseases were 0.064 for measurements based on the EQ-5D-3L, 0.061 for measurements based on the EQ-5D-5L, and 0.073 for measurements based on the SF-6D, which is regarded as the between-group MID in the general population. If symptoms were used in the same analysis, the differences were 0.093 for both the EQ-5D-3L and EQ-5D-5L and 0.112 for the SF-6D. Considering our results, the between-group MID can be estimated to range between 0.05 and 0.1 for all three measures.

Discussion

To our knowledge, this is the first study to examine the Japanese population norms of three preference-based QOL measures: the EQ-5D-3L, EQ-5D-5L, and SF-6D. Sampling was based on the Basic Resident Register data for each municipality. This sampling is regarded as one of the most rigid and reliable methods in Japan. The reason for the differences in the QOL scores, compared with the population norms in other countries, is unclear; however, the differences may be influenced by (a) differences in actual health states, (b) differences in the value sets used in each country, and/or (c) differences in the degree of the ceiling effect or other characteristics. The ceiling effect of the EQ-5D-3L (especially for pain/discomfort among younger respondents) may be higher in the present study than in western countries [12]. Of note, the difference in the population norms does not necessarily indicate a difference in the respondents' health states.